Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.

During embryonic development, the intestine of the Drosophila fly divides into distinct chambers thanks to the formation of ...

Researchers have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer's disease.

In Nature Neuroscience, UConn School of Medicine researchers have revealed a new scientific clue that could unlock the key ...

Bone morphogenetic proteins (BMPs) directly affect the osteogenic differentiation of stem cells and are integral to bone ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, of Dana-Farber Cancer Institute have been elected ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

CD8+ T cells accumulate in atherosclerotic plaques. LMU researchers identify a crucial signaling pathway - with therapeutic potential. Atherosclerosis is the most common cause of life-threatening ...